Research programme: CNS imaging agents - CleraAlternative Names: CLR 901
Latest Information Update: 21 Jan 2014
At a glance
- Originator Clera
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neurological disorders
Most Recent Events
- 01 Jan 2014 Discontinued - Preclinical for Neurological disorders in Canada (unspecified route)
- 07 Mar 2006 Preclinical trials in Diagnostic imaging in Canada (unspecified route)